Todays Report: Today, Q3 2016 Earnings Forecast for Gilead Sciences Inc. Issued By Jefferies Group (GILD)

Today, Q3 2016 Earnings Forecast for Gilead Sciences Inc. Issued By Jefferies Group (GILD)

Gilead Sciences Inc. (NASDAQ:GILD) – Analysts at Jefferies Group lowered their Q3 2016 EPS estimates for Gilead Sciences in a report released on Wednesday. Jefferies Group analyst B. Abrahams now expects that the brokerage will post earnings of $2.87 per share for the quarter, down from their previous estimate of $2.89. Jefferies Group has a “Buy” rating and a $93.00 price objective on the stock. Jefferies Group also issued estimates for Gilead Sciences’ Q4 2016 earnings at $2.79 EPS, FY2016 earnings at $11.66 EPS and FY2017 earnings at $10.76 EPS.

A number of other research analysts have also recently commented on GILD. Piper Jaffray Cos. lowered their price target on Gilead Sciences from $114.00 to $108.00 and set an “overweight” rating on the stock in a report on Tuesday, July 26th. Royal Bank Of Canada lowered their price target on Gilead Sciences from $120.00 to $105.00 and set an “outperform” rating on the stock in a report on Tuesday, July 26th. Robert W. Baird reissued an “outperform” rating and issued a $122.00 price target (down from $135.00) on shares of Gilead Sciences in a report on Tuesday, July 26th. Credit Suisse Group AG reissued a “buy” rating and issued a $115.00 price target (down from $120.00) on shares of Gilead Sciences in a report on Tuesday, July 26th. Finally, Needham & Company LLC cut Gilead Sciences from a “buy” rating to a “hold” rating and boosted their price target for the stock from $84.60 to $88.55 in a report on Tuesday, July 26th. Ten research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company. Gilead Sciences presently has a consensus rating of “Buy” and a consensus target price of $104.71.

Shares of Gilead Sciences (NASDAQ:GILD) opened at 76.21 on Thursday. The stock has a market cap of $100.57 billion, a price-to-earnings ratio of 6.69 and a beta of 1.10. The stock’s 50 day moving average price is $79.10 and its 200-day moving average price is $85.17. Gilead Sciences has a 1-year low of $76.07 and a 1-year high of $111.11.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, beating analysts’ consensus estimates of $3.02 by $0.06. The firm earned $7.78 billion during the quarter, compared to analyst estimates of $7.80 billion. Gilead Sciences had a return on equity of 106.75% and a net margin of 50.50%. The business’s quarterly revenue was down 5.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $3.15 earnings per share.

A number of institutional investors have recently modified their holdings of the company. Van Hulzen Asset Management LLC increased its position in shares of Gilead Sciences by 9.1% in the second quarter. Van Hulzen Asset Management LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 100 shares in the last quarter. Joel Isaacson & Co. LLC increased its position in shares of Gilead Sciences by 20.8% in the second quarter. Joel Isaacson & Co. LLC now owns 1,310 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 226 shares in the last quarter. Roble Belko & Company Inc increased its position in shares of Gilead Sciences by 340.5% in the second quarter. Roble Belko & Company Inc now owns 1,339 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 1,035 shares in the last quarter. Loomis Sayles & Co. L P increased its position in shares of Gilead Sciences by 23.3% in the first quarter. Loomis Sayles & Co. L P now owns 1,591 shares of the biopharmaceutical company’s stock worth $146,000 after buying an additional 301 shares in the last quarter. Finally, Pinkerton Retirement Specialists LLC increased its position in shares of Gilead Sciences by 9,305.9% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,599 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 1,582 shares in the last quarter. Institutional investors own 77.94% of the company’s stock.

In other Gilead Sciences news, insider John F. Milligan sold 70,000 shares of the stock in a transaction that occurred on Tuesday, September 6th. The stock was sold at an average price of $77.74, for a total transaction of $5,441,800.00. Following the transaction, the insider now owns 1,128,963 shares in the company, valued at $87,765,583.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John C. Martin sold 100,000 shares of the stock in a transaction that occurred on Monday, October 3rd. The stock was sold at an average price of $77.63, for a total value of $7,763,000.00. Following the transaction, the insider now owns 3,231,096 shares in the company, valued at approximately $250,829,982.48. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.

The business also recently announced a quarterly dividend, which was paid on Thursday, September 29th. Investors of record on Friday, September 16th were issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 2.47%. The ex-dividend date was Wednesday, September 14th. Gilead Sciences’s dividend payout ratio (DPR) is 16.56%.

Gilead Sciences Company Profile

Related posts

Leave a Comment